|Supplied by:||European Collection of Authenticated Cell Cultures (ECACC)|
|Culture Type:||Cell line|
|Collection:||ECACC General Collection|
|Cell Line Name:||PEA2|
|Citation Guidance:||If use of this culture results in a scientific publication, it should be cited in the publication as: PEA2 (ECACC 10032307)|
|Keywords:||Human ovarian cancer; oestrogen receptor positive|
|Cell Line Description:||
PEA2 is an adherent cell line derived from a malignant effusion from the peritoneal ascites of a patient with a poorly differentiated adenocarcinoma. PEA2 was collected on relapse after treatment with cisplatin and prednimustine. PEA2 exhibits poor growth in semi-solid medium (agar). PEA2 is from the same patient as the PEA1 cell line (ECACC Catalogue number 10032306).
This cell line is one of nine from the PE ovarian adenocarcinoma panel (derived from 4 patients at varying stages of ovarian cancer, isolated from various malignant sites, and at various treatment stages) available at ECACC which provides a model system for research into the mechanism of oestrogen action on ovarian adenocarcinoma tumour cells, and for the study of efficacy and toxicity of oestrogen protagonists.
|Tissue of Origin:||Ovary|
|CellType:||Epithelial; swirling pattern of cells.|
|Karyotype:||For modal chromosome numbers see Langdon SP et.al. (1988) Cancer Research Nov 1; 48(21):6166-72.|
Unless specified otherwise, at the European Collection of Authenticated Cell Cultures (ECACC) we routinely handle all of our cell lines at containment level 2 in accordance with the ACDP guidelines. ACDP = Advisory Committee on Dangerous Pathogens (UK)
All cell cultures have the potential to carry as yet unidentified adventitious agents. It is the responsibility of the end user to ensure that their facilities comply with biosafety regulations for their own country.
ACDP Guidance: Biological agents: Managing the risks in laboratories and healthcare premises.
Hyperlinks to MSDS documents:
Frozen cell cultures Material Safety Data Sheet
Growing cell cultures Material Safety Data Sheet
Nucleic acids derived from cell cultures Material Safety Data Sheet
|Subculture Routine:||Splitsub-confluent cultures (70-80%) 1:4 to 1:10 seeding at 2- 3 x 104 cells/cm2 using 0.05% trypsin or trypsin/EDTA; 5% CO2; 37°C. Doubling time approximately 66 hours.|
|Culture Medium:||RPMI 1640 + 2mM Glutamine + 2mM Sodium Pyruvate + 10% Foetal Bovine Serum (FBS).|
|Depositor:||Licensed from: Cancer Research Technology Ltd Angel Building 407 St John Street London EC1V 4AD|
|References:||Langdon SP et.al. (1988) Characterization and properties of nine human ovarian adenocarcinoma cell lines. Cancer Research Nov 1; 48(21):6166-72. PMID: 3167863.|
|Additional Bibliography:||Langdon SP et.al. (1990) Oestrogen receptor expression and the effects of oestrogen and tamoxifen on the growth of human ovarian carcinoma cell lines. British Journal of Cancer Aug; 62(2):213-6. PMID: 2386737.|
|Patents:||None specified by Depositor|
|Release Conditions:||Yes - commercial organisations are required to complete the 'Cell Line Release Authorisation for Research Use in Commercial Organisations' release conditions form.|
The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.
Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.
Please confirm your country of origin from the list below.